Literature DB >> 16621198

Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin.

Joel R Haynes1, Joshua Arrington, Lichun Dong, Ralph P Braun, Lendon G Payne.   

Abstract

A mouse model was employed to evaluate protective cellular immune responses induced by an immediate early antigen of HSV-2. Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice, but little protection to intranasal challenge with wild type HSV-2. However, when the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality. The ICP27+LT-mediated protection was correlated with a large increase in ICP27-specific IFN-gamma and TNF-alpha production but cytokine-specific monoclonal antibody treatment at the time of challenge showed that protection was mediated predominantly by IFN-gamma. Furthermore, depletion of T cell subsets prior to infectious challenge demonstrated that removal of either CD8+ or CD4+ T cells impaired protection with CD8+ T cells appearing to play a direct effector role. These data demonstrate that augmented cellular immune responses resulting from LT vector plus antigen vector administration to the skin are biologically significant, leading to enhanced protection against mucosal pathogenic challenge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621198     DOI: 10.1016/j.vaccine.2006.03.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

Authors:  Tansi Khodai; Debbie Chappell; Clare Christy; Paul Cockle; Jim Eyles; Daisy Hammond; Katrina Gore; Michael J McCluskie; Dana M Evans; Susanne Lang; Peter T Loudon; Tim Townend; Paul Wright; Kate West; Helen Bright
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

3.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Authors:  Nicolas Çuburu; Kening Wang; Kyle N Goodman; Yuk Ying Pang; Cynthia D Thompson; Douglas R Lowy; Jeffrey I Cohen; John T Schiller
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

5.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Authors:  Nicholas Farley; David I Bernstein; Fernando J Bravo; Julie Earwood; Nancy Sawtell; Rhonda D Cardin
Journal:  Antiviral Res       Date:  2010-02-16       Impact factor: 5.970

6.  Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection.

Authors:  William J Muller; Lichun Dong; Adrian Vilalta; Benjamin Byrd; Kai M Wilhelm; Christopher L McClurkan; Michal Margalith; Chao Liu; David Kaslow; John Sidney; Alessandro Sette; David M Koelle
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

Review 7.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

8.  Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Premeela Rajakumar; Jenny W Che; Amithi Narendran; Julia Nyaundi; Heather Michael; Eric J Yager; Cristy Stagnar; Brendon Wahlberg; Rachel Taber; Joel R Haynes; Fiona C Cook; Peter Ertl; John Tite; Angela M Amedee; Michael Murphey-Corb
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

9.  Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.

Authors:  Joseph W Golden; Matthew Josleyn; Eric M Mucker; Chien-Fu Hung; Peter T Loudon; T C Wu; Jay W Hooper
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  Mechanisms of immunization against cancer using chimeric antigens.

Authors:  Manuel E Engelhorn; José A Guevara-Patiño; Taha Merghoub; Cailian Liu; Cristina R Ferrone; Gabriele A Rizzuto; Daniel H Cymerman; David N Posnett; Alan N Houghton; Jedd D Wolchok
Journal:  Mol Ther       Date:  2008-02-26       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.